![EMJ Dermatology 9 [Supplement 1] 2021 Front Cover](https://emj.emg-health.com/wp-content/uploads/sites/2/2020/12/EMJ-Dermatology-9-Supplement-1-2021-Front-Cover.jpg)
At the 2020 European Academy of Dermatology and Venerology (EADV) Virtual Congress, data for 5-year efficacy and safety of tildrakizumab in adults with moderate-to-severe plaque psoriasis were presented across six posters. Overall, it was shown that tildrakizumab has a very favourable long-term efficacy and safety profile.
Login to continue
Members
Create Account
Create your own personal healthcare feed, full of the latest content from across our divisions.
Register
